利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

134 条记录 (耗时 0.031 秒)

    Process For Preparing 4-Pentafluorosulfanylbenzoylguanidines
    11.
    发明申请
    Process For Preparing 4-Pentafluorosulfanylbenzoylguanidines 有权
    4-五氟苯硫基苯甲酰胍的制备方法

    公开(公告)号：US20070106094A1

    公开(公告)日：2007-05-10

    申请号：US11539237

    申请日：2006-10-06

    申请人： Gerrit Schubert ,  Heinz-Werner Kleemann

    发明人： Gerrit Schubert ,  Heinz-Werner Kleemann

    IPC分类号： C07C309/00

    CPC分类号： C07C381/00

    摘要： A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formal I are NEH1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.

    摘要翻译： 制备式I的4-五氟硫基苯甲酰胍的方法，其中R 1至R 4具有说明书中所示的含义。 形式I的化合物是NEH 1抑制剂，可用于例如治疗心血管疾病。

    Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them
    12.
    发明授权
    Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them 失效
    取代的降冰片基氨基衍生物，其制备方法，它们作为药物或诊断剂的用途，以及包含它们的药物

    公开(公告)号：US06825231B2

    公开(公告)日：2004-11-30

    申请号：US09734008

    申请日：2000-12-12

    申请人： Uwe Heinelt ,  Hans-Jochen Lang ,  Heinz-Werner Kleemann ,  Jan-Robert Schwark ,  Klaus Wirth ,  Hans-Willi Jansen

    发明人： Uwe Heinelt ,  Hans-Jochen Lang ,  Heinz-Werner Kleemann ,  Jan-Robert Schwark ,  Klaus Wirth ,  Hans-Willi Jansen

    IPC分类号： A61K31335

    CPC分类号： C07C317/32 ,  C07B2200/07 ,  C07C211/38 ,  C07C211/49 ,  C07C215/30 ,  C07C217/58 ,  C07C217/60 ,  C07C217/62 ,  C07C229/38 ,  C07C237/30 ,  C07C255/58 ,  C07C257/18 ,  C07C311/37 ,  C07C323/32 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/68

    摘要： The application discloses substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics and a medicament comprising them Substituted norbornylamino derivatives having exo-configured nitrogen and an endo-fused five-membered ring of the formula I, or having exo-configured nitrogen and an exo-fused five-membered ring of the formula I a in which R1, R2, R3, R4, R5, A, B, S1, and S2 are as defined in the claims, are highly suitable for use as antihypertensive agents, for reducing or preventing ischemically induced damage, for use as medicaments for surgical interventions for the treatment of ischemias of the nervous system, of stroke and cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxatives, as agents against ectoparasites, for the prevention of the formation of biliary calculus, as antiatherosclerotics, as agents against late diabetic complications, carcinomatous disorders, fibrotic disorders, endothelial dysfunction, and organ hypertrophies and hyperplasias. They are inhibitors of the cellular sodium/proton antiporter. They have an influence on serum lipoproteins and can therefore be used for the prophylaxis and regression of atherosclerotic changes.

    摘要翻译： 本申请公开了取代的降冰片烷基氨基衍生物，其制备方法，它们作为药物或诊断剂的用途，以及包含它们的药物具有外部构型的氮的取代的降冰片烷基氨基衍生物和式I的内部稠合的五元环，或具有外部配置的氮 和R 1，R 2，R 3，R 4，R 5，A，B，S 1和S 2如权利要求中所定义的式I ain的外部稠合的五元环非常适合用作抗高血压剂，用于 减少或预防缺血性损伤，用作外科手术治疗神经系统缺血，中风和脑水肿，休克，呼吸驱动受损，用于治疗打鼾的药物，作为泻药，作为药物 外寄生虫，用于预防胆汁结石的形成，作为抗动脉粥样硬化，作为晚期糖尿病并发症的药剂，癌性疾病，纤维化疾病，en 上皮功能障碍，器官肥厚和增生。它们是细胞钠/质子逆转录酶的抑制剂。 它们对血清脂蛋白有影响，因此可用于预防和消除动脉粥样硬化变化。

    Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid
    13.
    发明授权
    Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid 失效
    二氢噻吩并萘甲酰胍：组合物，制备方法和用作药物或诊断助剂

    公开(公告)号：US06730697B2

    公开(公告)日：2004-05-04

    申请号：US10350520

    申请日：2003-01-23

    申请人： Heinz-Werner Kleemann ,  Peter Below

    发明人： Heinz-Werner Kleemann ,  Peter Below

    IPC分类号： A61K3138

    CPC分类号： C07D335/10

    摘要： Dihydrothiaphenanthrenecarbonylguanidine compound of formula I These compounds are potentially suitable as antiarrythmic medicaments with a cardioprotective component for prophylaxis of an infarction and treatment of infarction, and for treatment of angina pectoris. They may also inhibit in a preventive manner the pathophysiological processes involved in the development of ischemia-induced damage, especially in the initiation of ischemia-induced cardiac arrhythmias.

    摘要翻译： 式II的二氢噻吩并呋喃羰基胍化合物这些化合物潜在地适合作为抗心律失常药物，其具有用于预防梗死和治疗梗死的心脏保护组分，以及用于治疗心绞痛。 它们还可以以预防的方式抑制涉及缺血诱导的损伤发展的病理生理过程，特别是在引发缺血诱发的心律失常中。